New insider activity at Twist Bioscience ( (TWST) ) has taken place on February 19, 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Twist Bioscience has reported an insider transaction by its SVP of Human Resources, Paula Green, who sold 39,404 shares of the company’s stock. The total value of this sale amounts to $2,064,769, signaling a significant disposal of shares by a senior executive.
Recent Updates on TWST stock
Twist Bioscience shares reacted to news of a broadened partnership with Invenra, where Twist secured co-exclusive rights to Invenra’s bispecific antibody platform, future license revenue streams, and a ~6% equity stake plus board representation, bolstering its antibody discovery and strategic positioning. Analysts raising price targets cited Twist’s stronger-than-expected Q4 results, upgraded FY2026 revenue guidance, momentum from NGS market normalization, and growing AI-driven drug discovery demand, supporting expectations for solid growth despite ongoing losses and cash-flow weakness.
Spark’s Take on TWST Stock
According to Spark, TipRanks’ AI Analyst, TWST is a Neutral.
The score is held back primarily by still-negative cash flow and ongoing losses despite improving margins and a reasonable balance sheet. Offsetting this are strong technical momentum and a constructive earnings outlook with raised FY2026 guidance and a stated path to adjusted EBITDA breakeven, while valuation remains challenging given the negative earnings profile.
To see Spark’s full report on TWST stock, click here.
More about Twist Bioscience
YTD Price Performance: 73.14%
Average Trading Volume: 1,400,111
Technical Sentiment Signal: Buy
Current Market Cap: $3.24B